Molecular Mechanisms Underlying Prostate Cancer Disparities
| Status: | Recruiting |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/21/2019 |
| Start Date: | November 2014 |
| End Date: | January 30, 2020 |
| Contact: | Monika Anand |
| Email: | monika.anand@duke.edu |
| Phone: | 919.681.8838 |
Molecular Mechanisms Underlying Prostate Cancer Disparities.
The purpose of this study is to further elucidate the molecular mechanisms underlying
prostate cancer disparities. In previous work the investigators have identified a set of
differentially deregulated genes in African American versus Caucasian American prostate
cancer. Based on these findings, they hypothesize that they will be able to validate these
targets, originally identified in the previous work conducted at The George Washington
University Medical Center, in an independent Duke University Medical Center cohort of
prostate cancer specimens. In addition, the investigators hypothesize that they will be able
to discover novel targets in the Duke University Medical Center cohort of prostate cancer
specimens because of regional differences.
prostate cancer disparities. In previous work the investigators have identified a set of
differentially deregulated genes in African American versus Caucasian American prostate
cancer. Based on these findings, they hypothesize that they will be able to validate these
targets, originally identified in the previous work conducted at The George Washington
University Medical Center, in an independent Duke University Medical Center cohort of
prostate cancer specimens. In addition, the investigators hypothesize that they will be able
to discover novel targets in the Duke University Medical Center cohort of prostate cancer
specimens because of regional differences.
Individual patient African American and Caucasian American prostate biopsy cores or surgical
specimens will be obtained from the following procedures: transrectal ultrasound biopsy of
the prostate (TRUSBxP), MR fusion biopsy, intra-operatively (IO) at the time of
prostatectomy. Using cellular DNA and RNA, isolated from prostate cancer and patient-matched
normal prostate biopsy cores or surgical specimens, the investigators will perform ancestral
genotyping, exon arrays, targeted RNA sequencing, and epigenetic analyses. As controls, blood
will also be collected. Genomic data from blood and tumor tissue will be compared.
specimens will be obtained from the following procedures: transrectal ultrasound biopsy of
the prostate (TRUSBxP), MR fusion biopsy, intra-operatively (IO) at the time of
prostatectomy. Using cellular DNA and RNA, isolated from prostate cancer and patient-matched
normal prostate biopsy cores or surgical specimens, the investigators will perform ancestral
genotyping, exon arrays, targeted RNA sequencing, and epigenetic analyses. As controls, blood
will also be collected. Genomic data from blood and tumor tissue will be compared.
Inclusion Criteria:
- Suspected malignancy of prostate cancer
- Self-reported race of African American or Caucasian American
- Age >/= 18 years
- Able to read, understand and sign an informed consent document
Exclusion Criteria:
- Collected tumor tissue is inadequate for DNA and RNA analysis and/or is not positive
for adenocarcinoma of the prostate.
- Patients with prior systemic therapy will not be eligible for the study, i.e.
radiation or chemo or immunotherapy.
We found this trial at
1
site
2301 Erwin Rd
Durham, North Carolina 27710
Durham, North Carolina 27710
919-684-8111
Principal Investigator: Steven Patierno, PhD
Phone: 919-681-8838
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials
